CeQur, Medtronic, Roche, and Biocorp made moves in the diabetes market.
CeQur has raised $115 million in an oversubscribed equity financing. The Lucerne, Switzerland-based company has developed CeQur Simplicity, a wearable insulin delivery system.
Credit Suisse Entrepreneur Capital Ltd. and Endeavour Vision led the financing with significant participation from new investors, including Tandem Diabetes Care, Ypsomed Group, Federated Hermes Kaufmann Funds, Kingdon Capital, and GMS Capital, as well as existing investors, Schroder & Co. Bank SA, and VI Partners.
Proceeds from the financing will be used to advance commercial plans for CeQur Simplicity, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing.
Apr 13, 2021 11:58am The Mallya device, compatible with most disposable insulin pens, automatically transmits daily insulin data to diabetes patients’ healthcare providers via Roche’s Gluci-Chek app. (Roche)
Need to automatically compile data gathered by an insulin pen and send it to a healthcare provider? There’s a device-connected app for that.
Less than a year after signing their initial distribution agreement, Roche Diabetes Care France has begun making Biocorp’s Mallya device available in pharmacies across France.
The French device maker’s smart sensor connects to most disposable insulin injection pens to collect data about each injection. Mallya automatically transmits that data to Roche’s Gluci-Chek smartphone app over Bluetooth. The dosage, insulin type, date and time information can then be logged and shared with healthcare providers via the Roche Diabetes Care Platform.